Resources
About Us
Veterinary Molecular Diagnostics Market by Product (Kits & Reagents, System & Software), Technology (PCR, Microarray, DNA Seq), Animal Type (Companion, Livestock), Application (Infectious Disease, Genetics), End User (Hospital, Clinical Lab) - Forecast to 2029
Report ID: MRHC - 104598 Pages: 250 May-2022 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours Download Free Sample ReportThe Veterinary Molecular Diagnostics Market is expected to grow at a CAGR of 9.2% from 2022 to 2029 to reach $1.13 billion by 2029. Factors such as the growing pet animal population, high animal healthcare expenditure, ongoing advancements in veterinary molecular diagnostics, and the high sensitivity and specificity of MDx tests are supporting the market growth. Moreover, emerging markets, advancements in veterinary diagnostics technologies, and increasing efforts by organizations to promote animal welfare are expected to offer opportunities for the global veterinary molecular diagnostics market.
Since the outbreak of COVID-19, SARS-CoV-2 infections have been reported in a small number of animals worldwide, mostly in animals that had close contact with a sick person with COVID-19. As the COVID-19 outbreak continues to take its toll on global markets, the veterinary molecular diagnostics market will be affected in the upcoming years as there is a surge in the development of veterinary diagnostics products for protecting and animal diagnosis.
Few pet cats and dogs have been infected with the virus in several countries, including the U.S. For instance, in June 2020, the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories (NVSL) reported the first confirmed case of SARS-CoV-2 (the virus that causes COVID-19) infection in a pet dog (German shepherd) in New York state. Similarly, in April 2020, the U.S. Centers for Disease Control and Prevention (CDC) and the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories (NVSL) announced confirmed cases of SARS-CoV-2 (the virus that causes COVID-19) infection in two pet cats which got infected as their owner had tested positive for COVID-19.
Click here to: Get Free Request Sample Copy of this report
The animals are being tested for SARS-CoV-2 infection and tested to see whether the pet develops antibodies to this virus. Various molecular diagnostics-based assays are being developed for testing infection in animals. For instance, in April 2020, IDEXX Laboratories, Inc. (U.S.) launched the IDEXX SARS-CoV-2 (COVID-19) RealPCR Test for pets.
Thus, several studies are underway to learn more about coronavirus infection in animals. This is expected to lead to the development of various molecular diagnostics-based assays and kits for testing, leading to increased adoption of veterinary molecular diagnostic products.
Rising Prevalence of Zoonotic Diseases to Drive the Growth of the Veterinary Molecular Diagnostics Market
Global urbanization is causing increasingly frequent contact between wildlife, human and domestic animal populations, resulting in increased zoonotic disease spillover from wildlife populations. Animal rearing, slaughter, preparation, and food consumption practices can further promote the transmission of infectious animal and zoonotic diseases. Animals can sometimes appear healthy even when carrying germs that make people sick, depending on the zoonotic disease. As animals also provide food for consumption, foodborne zoonotic diseases are caused by consuming food or water contaminated by pathogenic microorganisms. According to CDC, more than 6 out of every ten known infectious diseases in people can be spread from animals, and 3 out of every four new or emerging infectious diseases in people come from animals.
According to WHO, an estimated 600 million, i.e., almost 1 in 10 people worldwide, fall ill from consuming contaminated food every year. Children under five years of age are at a particularly high risk of carrying 40% of the burden of foodborne diseases, with 125,000 children dying from foodborne diseases every year. Diarrheal diseases are the most common illnesses resulting from the consumption of contaminated food, causing 550 million people to fall ill and 230,000 deaths every year (Source: WHO). According to the Centers for Disease Control (CDC), in 2020, nearly 18,462 foodborne disease infections were witnessed in the U.S., including 4,788 hospitalizations and 118 deaths. Also, WHO states that the total productivity loss associated with foodborne disease in low-and middle-income countries was USD 110 billion in 2020.
As zoonotic diseases spread from animals to humans and from humans to animals, 61% of the infectious diseases affecting humans are zoonotic; 75% of new or emerging diseases worldwide are zoonotic. Thus, PoC diagnosis and management decisions can prevent onward transmission of infectious pathogens, protecting the health and wellbeing of human and animal populations worldwide and potentially containing epidemics that would otherwise have serious and far‐reaching consequences.
In 2022, the Polymerase Chain Reaction Segment is Estimated to Dominate the Veterinary Molecular Diagnostics Market
On the basis of technology, the PCR segment is estimated to account for the largest share of this market in 2022. PCR tests are used in the early stages of an infection, where the level of infection is often below the detection limit (or in the latent phase) of conventional methods. It gives an immediate response to the current infection i.e. PCR offers information about the animal’s current infection status and therefore offers significant value to veterinarians and farmers. The use of techniques, such as PCR and real-time PCR, has led to the development of assays that decrease the problems associated with cross-contamination among samples and facilitates. Thus, these factors are expected to drive the market for this segment.
Based on Product, the Kits & Reagents Segment is Estimated to Grow at the Highest CAGR During the Forecast Period
On the basis of product, in 2022, the kits & reagents segment is estimated to account for the largest share of the veterinary molecular diagnostics market. The large share of this segment is mainly attributed to the fact that they are frequently used and the availability of a diverse range of reagents and consumables for various diseases.
In 2022, the Companion Animals Segment is Estimated to Account for the Largest Share of the Veterinary Molecular Diagnostics Market
On the basis of animal type, the companion animals segment is estimated to account for the largest share of the market in 2022. Companion animals can act as a carrier of diseases that infect humans (i.e. zoonotic disease). Therefore, the care and concern by pet owners regarding the health and wellbeing of companion animals are increasing. In recent years, infection of various diseases in companion animals has increased, leading companion diagnostic providers to develop new devices and tests. Also, increasing awareness among pet owners to regularly diagnose glucose levels increases the demand for glucose monitors. Further, companies are developing newer diagnostic products, helping expand the segment.
Asia Pacific: Fastest-growing Market
The factors driving the growth of the Asia-Pacific veterinary molecular diagnostics market are the large population of livestock animals, rising incidence of various zoonotic diseases, and focus on adopting newer molecular technologies in animal healthcare.
Key Players
The report includes a competitive landscape based on extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments in leading industry market players over the past four years . The key players profiled in the global veterinary molecular diagnostics market are IDEXX Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), Neogen Corporation (U.S.), Heska Corporation (U.S.), Biomedica Medizinprodukte GmbH & Co KG (Austria), VCA, Inc. (U.S.), Novacyt Group (U.K.), QIAGEN N.V. (Germany), and BioChek B.V (Netherlands).
Scope of the Report:
Veterinary Molecular Diagnostics Market, by Product
Veterinary Molecular Diagnostics Market, by Application
Veterinary Molecular Diagnostics Market, by Technology
Veterinary Molecular Diagnostics Market, by Animal Type
Veterinary Molecular Diagnostics Market, by End User
Veterinary Molecular Diagnostics Market, by Geography
Key questions answered in the report:
The global veterinary molecular diagnostics market is projected to reach $1.13 billion by 2029, at a CAGR of 9.2% during the forecast period.
Published Date: Jul-2024
Published Date: Jul-2024
Published Date: Jul-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates